| Name | Title | Contact Details |
|---|---|---|
Jacqui Boire |
Director, Technology Strategy and Planning | Profile |
PharmaLinkFHI (PharmaLink) is the first full-service Clinical Research Organization (CRO) to integrate clinical and technological expertise in managing Phase I-IV clinical trials online in real time. Biopharmaceutical and medical device organizations
Please select your location. United States International
Cambrex is the leading small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle. Enjoy working with our experts to accelerate your small molecule therapeutics into the market.
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
CSI TESTING Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.